OR WAIT null SECS
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
This article discusses the potential of using high-productivity membrane chromatography to achieve intensified and flexible virus manufacturing.
Most vaccines available today are still manufactured using antiquated, low-yield, and labor-intensive process technologies in capital-intensive facilities. This lack of manufacturing flexibility drives high cost of goods, diminishes affordability for developing countries, and reduces the market incentive to address smaller patient populations. Improved manufacturing technologies can enable more efficient and cost-effective processes. This article discusses the potential of using high-productivity membrane chromatography to achieve intensified and flexible virus manufacturing.
Pharmaceutical Technology and BioPharm International
eBook: Vaccine Development and Manufacturing 2017
When referring to this article, please cite it as R. Jacquemart et al., “Achieving Intensification and Flexibility in Virus Purification with Next-Generation Chromatography Tools,” Pharmaceutical Technology and BioPharm International Vaccine Development and Manufacturing 2017 eBook (November 2017).